Pyrazone 200 mg
Sulfinpyrazone
Category: Tablet
Manufacturer: Incepta Pharmaceuticals Ltd.
Allopathic
MFG. Licence No. Biological
193
MFG. Licence No. Non-Biological
108
Address
Zirabo, Savar, Dhaka Dewan Idris Road, Bara Rangamatia
Price: 36.0 ৳
Tablet
Medicine Selling service is not available yet.
Related Medicines
Hyperuricaemia with gout
Hypersensitivity to sulfinpyrazone and other pyrazolone derivatives. Patient in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other drugs w/ prostaglandin-synthetase inhibiting activity. Acute gout attack, blood coagulation disorders, uric acid renal calculi, porphyria, peptic ulceration, severe parenchymal lesions of liver or kidneys, blood dyscrasias. Severe hepatic and renal impairment. Concomitant use w/ salicylates.
Administration:
Should be taken with food.
Adult Dose:
Oral
Hyperuricaemia with gout
Adult: Initially, 100-200 mg bid, increase gradually over 2-3 wk to 600 mg daily. Maintenance dose (after plasma-urate concentration is controlled): 200 mg daily in divided doses. Max: 800 mg daily.
Hepatic impairment: Severe: Avoid.
Renal Dose:
Renal impairment: Mild to moderate: Reduce dose. Severe: Contraindicated.
Decreased therapeutic effect when given w/ drugs that increase uric acid concentration (e.g. diuretics, pyrazinamide). May potentiate the action of coumarin anticoagulants (e.g. warfarin, acenocoumarol), hypoglycaemic agents and sulfonamides. May decrease plasma levels of theophylline. May increase plasma levels of penicillins and phenytoin. Increased risk of haemorrhage w/ substances affecting homeostasis (e.g. non-steroidal antirheumatic drugs). Probenecid may inhibit renal tubular secretion of sulfinpyrazone.
Potentially Fatal: Salicylates may antagonise the effect of sulfinpyrazone.
Hypersensitivity to sulfinpyrazone and other pyrazolone derivatives. Patient in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other drugs w/ prostaglandin-synthetase inhibiting activity. Acute gout attack, blood coagulation disorders, uric acid renal calculi, porphyria, peptic ulceration, severe parenchymal lesions of liver or kidneys, blood dyscrasias. Severe hepatic and renal impairment. Concomitant use w/ salicylates.
Nausea, vomitting, diarrhoea, skin rashes, renal impairment or failure, salt and water retention, blood dyscrasia, jaundice, hepatitis, acute gout attacks, uric acid renal calculi development if inadequate fluid intake.
Precaution:
Patient w/ heart failure. Mild to moderate renal impairment. Pregnancy and lactation. Patient Counselling Ensure adequate fluid intake (approx 2-3 L/day) and urine alkalinisation. Monitoring Parameters Monitor renal function, blood count.
Symptoms: Nausea, vomiting, diarrhea, epigastric pain, laboured respiration, convulsions and coma. Treatment: No specific antidote. Induce emesis, gastric lavage, supportive treatment (intravenous glucose infusions).
Store between 15-30° C.
Drugs used in Gout
Sulfinpyrazone increases urinary excretion of uric acid by inhibiting tubular reabsorption of uric acid. It also decreases platelet aggregation.
Pregnancy category C. This means that it is not known whether Sulphinpyrazone will harm an unborn baby. Don't take this without first talking to your doctor if you are pregnant.It is also not known whether Sulphinpyrazone passess into breast milk. Do not take it without first talking to your doctor if you are breast-feeding a baby.
Samm Care